Scholar Rock Holding Dirección

Dirección controles de criterios 3/4

El CEO de Scholar Rock Holding es Jay Backstrom , nombrado en Oct 2022, tiene una permanencia de 2.08 años. compensación anual total es $4.11M, compuesta por 15.2% salario y 84.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.028% de las acciones de la empresa, por valor de €743.72K. La antigüedad media del equipo directivo y de la junta directiva es de 2.1 años y 7.7 años, respectivamente.

Información clave

Jay Backstrom

Chief Executive Officer (CEO)

US$4.1m

Compensación total

Porcentaje del salario del CEO	15.2%
Permanencia del CEO	2.1yrs
Participación del CEO	0.03%
Permanencia media de la dirección	2.1yrs
Promedio de permanencia en la Junta Directiva	7.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jay Backstrom en comparación con los beneficios de Scholar Rock Holding?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$226m
Jun 30 2024	n/a	n/a	-US$204m
Mar 31 2024	n/a	n/a	-US$183m
Dec 31 2023	US$4m	US$624k	-US$166m
Sep 30 2023	n/a	n/a	-US$159m
Jun 30 2023	n/a	n/a	-US$160m
Mar 31 2023	n/a	n/a	-US$166m
Dec 31 2022	US$7m	US$159k	-US$135m

Compensación vs. Mercado: La compensación total de Jay($USD4.11M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.90M).

Compensación vs. Ingresos: La compensación de Jay ha sido consistente con los resultados de la empresa en el último año.

CEO

Jay Backstrom (69 yo)

2.1yrs

Permanencia

US$4,111,853

Compensación

Dr. Jay Thomas Backstrom, M.D., M.P.H., serves as Non-Executive Director of LAVA Therapeutics N.V. since June 2022. He serves as Director at Be Biopharma, Inc. since December 2021. He had served as a Direc...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jay Backstrom	President	2.1yrs	US$4.11m	0.028% € 743.7k
Edward Myles	CFO, COO & Treasurer	4.3yrs	US$2.01m	0% € 0
Tracey Sacco	Chief Commercial Officer	1.8yrs	US$2.28m	0% € 0
Mo Qatanani	Chief Scientific Officer	less than a year	sin datos	0.022% € 580.5k
Rushmie Nofsinger	Vice President of Corporate Affairs & Investor Relations	no data	sin datos	sin datos
Junlin Ho	General Counsel & Corporate Secretary	4.7yrs	US$2.13m	0.079% € 2.1m
Caryn Parlavecchio	Chief Human Resources Officer	3.3yrs	sin datos	0.043% € 1.1m
Lisa Price	Senior Vice President of Human Resources	no data	sin datos	sin datos
Erin Moore	Senior Vice President of Finance	no data	sin datos	sin datos
Ryan Iarrobino	Senior Vice President of Clinical Development & Operations	4.7yrs	sin datos	sin datos
Jing Marantz	Chief Medical Officer	2yrs	sin datos	0.078% € 2.1m
Beth Shafer	Chief Business Officer	less than a year	sin datos	sin datos

2.1yrs

Permanencia media

51.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2QK se considera experimentado (2.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jay Backstrom	President	2.1yrs	US$4.11m	0.028% € 743.7k
Michael Gilman	Independent Director & Member of Scientific Advisory Board	11yrs	US$299.20k	0.040% € 1.1m
Timothy Springer	Member of Scientific Advisory Board	no data	US$48.97k	sin datos
Jeffrey Flier	Independent Director & Member of Scientific Advisory Board	8.1yrs	US$305.70k	0.033% € 898.9k
Leonard Zon	Member of Scientific Advisory Board	no data	sin datos	sin datos
Daniel Rifkin	Member of Scientific Advisory Board	no data	sin datos	sin datos
Kristina Burow	Independent Director	10.3yrs	US$300.34k	0.0057% € 153.3k
Joan Massague	Member of Scientific Advisory Board	no data	sin datos	sin datos
David Hallal	Independent Chairman of the Board	7.3yrs	US$416.70k	0.31% € 8.3m
Scott L. Friedman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Barry Coller	Member of Scientific Advisory Board	no data	sin datos	sin datos
Joshua Reed	Independent Director	3.7yrs	US$305.70k	0% € 0

7.7yrs

Permanencia media

69yo

Promedio de edad

Junta con experiencia: La junta directiva de 2QK se considera experimentada (7.7 años de antigüedad promedio).

Scholar Rock Holding Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

President recently sold €170k worth of stock

Scholar Rock Announces Management Appointments

Senior VP & Head of Research recently sold €268k worth of stock

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Recent updates

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million.

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

New major risk - Financial position

Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

New major risk - Shareholder dilution

New major risk - Financial position

President recently sold €170k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Senior VP & Head of Research recently sold €268k worth of stock

New major risk - Revenue and earnings growth

Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability

Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Full year 2022 earnings released: US$2.26 loss per share (vs US$3.59 loss in FY 2021)

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer

Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Scholar Rock Announces Chief Executive Officer Changes

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021)

Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors

Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index

Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment

Scholar Rock Holding Corporation Provides Pipeline Updates

First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.76 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Scholar Rock Holding Corporation Provides Corporate Update and Highlights Priorities for 2022

Scholar Rock Holding Corporation Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

Third quarter 2021 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2020)

Scholar Rock Holding Corporation Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

Second quarter 2021 earnings released: US$0.84 loss per share (vs US$0.65 loss in 2Q 2020)

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress

Forecast to breakeven in 2025

Scholar Rock Announces Oral Presentation of TOPAZ Phase 2 Trail Results at the 2021 Virtual SMA Research & Clinical Care Meeting

Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting

Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy

Scholar Rock Holding Corporation to Present Trials in Progress Poster for Srk-181 Dragon Phase 1 Clinical Trial At the American Society of Clinical Oncology Annual Meeting

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.76 loss per share (vs US$0.58 loss in 1Q 2020)

Scholar Rock Announces Publication of Phase 1 Clinical Trial Data Evaluating Apitegromab in Healthy Volunteers in the Journal Advances in Therapy

Scholar Rock Announces the Addition of Joshua Reed to Its Board of Directors

Full year 2020 earnings released: US$2.81 loss per share (vs US$1.85 loss in FY 2019)

Revenue misses expectations

New 90-day high: €50.00

Scholar Rock Announces Executive Promotions

New 90-day high: €47.40

New 90-day high: €43.80

Third quarter 2020 earnings released: US$0.79 loss per share

Revenue misses expectations

New 90-day high: €31.80

Earnings released

Scholar Rock Holding Corporation to Report Q2, 2020 Results on Aug 07, 2020

Scholar Rock Holding Corporation Announces Executive Changes, Effective August 1, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación